{"id":"W3006140059","doi":"10.1007/s00280-020-04038-8","title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexen (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Tolerability; Trametinib; Dosing; Medicine; Rash; Adverse effect; Internal medicine; Mucositis; Oncology; Pharmacology; Toxicity; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001425458,0.0001568055,0.0002286441,0.00002709196,0.00004894675,0.00000937748,0.0001286052,0.0001056748,0.00003327586],"category_scores_gemma":[0.000008493539,0.00009154955,0.00003480144,0.0001961993,0.0001636395,0.00001083293,0.00002798735,0.0001605985,2.259684e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002077759,"about_ca_system_score_gemma":0.0001207346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000271517,"about_ca_topic_score_gemma":0.00009152128,"domain_scores_codex":[0.9990327,0.0001587118,0.0002366347,0.0002692028,0.0001195957,0.00018314],"domain_scores_gemma":[0.9996101,0.00001744894,0.0001627352,0.0001000051,0.00005783509,0.00005186294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1118161,0.001647779,0.03807384,0.00007640244,0.0001106344,0.000002707877,0.001770838,0.0001495272,0.8273017,0.00002254116,0.001439004,0.01758893],"study_design_scores_gemma":[0.1534005,0.006319862,0.01441906,0.00002631186,0.00003701599,8.584262e-7,0.00007982578,0.0002649537,0.8214734,0.0000143938,0.003773056,0.0001908296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965128,0.0001082187,0.00003810677,0.002044919,0.0001965178,0.001037217,0.00002338437,0.000005137809,0.00003372861],"genre_scores_gemma":[0.9977234,0.00004595072,0.00002903593,0.001808381,0.0002020189,0.0001175005,0.00003499031,0.00001871661,0.00001999853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04158439,"threshold_uncertainty_score":0.3733282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01414950799063345,"score_gpt":0.2872376165837309,"score_spread":0.2730881085930975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}